Recent Material Events - Arena Pharmaceuticals, Inc (ARNA)

Filing Date	Description
2008-07-09	On July 9, 2008, we announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound’s safety, pharmacokinetics and pharmacodynamics. APD791 is Arena’s internally discovered oral drug cand ...
2008-04-08	On April 8, 2008, we announced that we initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate we discovered with the potential to reduce insomnia symptoms and improve sleep maint ...
2008-03-17	On March 17, 2008, we announced that following a planned review by an independent Echocardiographic Data Safety Monitoring Board, or EDSMB, we are continuing BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), a pivo ...
2008-01-30	On January 25, 2008, the Compensation Committee of our Board of Directors approved the 2008 Annual Incentive Plan and 2008 corporate and individual goals for executive officers. ...
2008-01-25	On January 25, 2008, we announced that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under our collaboration with Merck to discover drugs for the treatment of atherosclerosis and other di ...
2007-12-13	On December 13, 2007, we announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of our lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obe ...
2007-10-17	On October 17, 2007, we issued a press release reporting our financial results for the third quarter ended September 30, 2007. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ...
2007-10-04	Our Board of Directors has approved an amendment and restatement of our Amended and Restated Bylaws, effective as of October 1, 2007, to revise Sections 1, 3 and 4 of Article V. The amendment allows for the issuance and transfer of both certificated ...
2007-09-25	On September 25, 2007, we announced preliminary results from our Phase 2 clinical trial of APD125 in patients with chronic insomnia. APD125 is an orally available drug candidate discovered by us that is being evaluated in insomnia patients who have d ...
2007-09-11	On September 11, 2007, we announced that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop our ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Ob ...